CytoDyn (OTCQB: CYDY), a biotechnology company, is focused
on providing a treatment to the millions of people infected with the human
immunodeficiency virus (HIV). A recent article discussing the company reads,
“HIV targets the immune system and weakens the body’s defense systems against
infections and some types of cancer. During 2017, some 1.8 million people
became newly infected with HIV, bringing the global total to 36.9 million
people living with HIV, according to the World Health Organization (http://ibn.fm/udfzb). HIV
continues to be a major public health issue, having claimed more than 35
million lives so far from every corner of the world. The market potential for
PRO 140 used as an anti-viral agent in combination with a patient’s current HIV
regimen (Highly Active Antiretroviral Therapy, or “HAART”) is $1.2 billion; as
a monotherapy maintenance/single-drug therapy, the market is estimated at $3.8
billion.”
To view the full article, visit http://ibn.fm/L2jRi
About CytoDyn
CytoDyn is a biotechnology company developing innovative
treatments for multiple therapeutic indications based on PRO 140 (leronlimab),
a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 plays a
key role in the ability of HIV to enter and infect healthy T-cells. The
CCR5 receptor is also implicated in tumor metastasis and in immune-mediated
illnesses such as graft-vs-host disease (GvHD) and NASH. CytoDyn has successfully
completed a Phase 3 pivotal trial with PRO 140 in combination with standard
anti-retroviral therapies in HIV-infected treatment-experienced patients. The
Company plans to seek FDA approval for PRO 140 in combination therapy and plans
to complete the filing of a Biological License Application (BLA) in the first
quarter of 2019 for that indication. CytoDyn is also conducting a Phase 3
investigative trial with PRO 140 as a once-weekly monotherapy for HIV-infected
patients, and plans to initiate a registration-directed study of PRO 140
monotherapy indication, which if successful, could support a label extension.
Clinical results to date from multiple trials have shown that PRO 140 can
significantly reduce viral burden in people infected with HIV with no reported
drug-related serious adverse events (SAEs). Moreover, results from a Phase 2b
clinical trial demonstrated that PRO 140 monotherapy can prevent viral escape
in HIV-infected patients, with some patients on PRO 140 monotherapy remaining
virally suppressed for more than four years. CytoDyn is also conducting a Phase
2 trial to evaluate PRO 140 for the prevention of GvHD and expects to initiate
clinical trials with PRO 140 in metastatic triple-negative breast cancer in
2018. For more information, visit the company’s website at www.CytoDyn.com
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
QualityStocks has received compensation from CytoDyn Inc.
for providing certain investor relations, marketing and social media services,
including the preparation of this report, and expects to receive additional
compensation for such services in the future. This compensation includes a
monthly program fee.
No comments:
Post a Comment